Explore

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Genprex Publishes Positive Biomarker Data for Reqorsa Gene Therapy at ASCO 2026

Genprex Publishes Positive Biomarker Data for Reqorsa Gene Therapy at ASCO 2026

Genprex Publishes Positive Biomarker Data for Reqorsa Gene Therapy at ASCO 2026

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

Brenus Pharma, a biotechnology company specializing in immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for STC-1010. This drug is designed to treat microsatellite stable (MSS) metastatic colorectal cancer (mCRC), a condition affecting approximately 95% of mCRC patients who typically show minimal response to standard immunotherapies. The FDA's approval allows Brenus Pharma to proceed with clinical evaluations in the U.S. under the BreAK-CRC001 study. This development follows European regulatory approvals and initial positive results from early Phase Ia trials. The company plans to present further data at the ESMO annual congress in 2026.

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Archeus Technologies Begins Phase 1 Trial for ARC-706 in Metastatic Cancer

Archeus Technologies Begins Phase 1 Trial for ARC-706 in Metastatic Cancer

Archeus Technologies Begins Phase 1 Trial for ARC-706 in Metastatic Cancer

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones